AR043106A2 - Formulaciones farmaceuticas para la administracion oral y topica y formas de dosis farmaceutica - Google Patents

Formulaciones farmaceuticas para la administracion oral y topica y formas de dosis farmaceutica

Info

Publication number
AR043106A2
AR043106A2 ARP030103268A ARP030103268A AR043106A2 AR 043106 A2 AR043106 A2 AR 043106A2 AR P030103268 A ARP030103268 A AR P030103268A AR P030103268 A ARP030103268 A AR P030103268A AR 043106 A2 AR043106 A2 AR 043106A2
Authority
AR
Argentina
Prior art keywords
ch2or
chor
ch2o
esters
unsaturated
Prior art date
Application number
ARP030103268A
Other languages
English (en)
Original Assignee
Ivax Cr A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10859192&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR043106(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ivax Cr A S filed Critical Ivax Cr A S
Publication of AR043106A2 publication Critical patent/AR043106A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)

Abstract

Una formulación farmacéuticamente para la administración oral o tópica que incluye: a) 0,1 a 30,0 % de uno o más ingredientes hidrofóbicos activos (ciclosporinas, entre otros); b) entre el 0,1 y el 60 % de uno o más compuestos formadores de gel seleccionados de poliglicerol ésteres de ácidos grasos de la fórmula : CH2OR-CHOR-CH2O-[CH2CHOR-CH2O-]NCH2-CHOR-CH2OR, donde n es un entero entre 4 y 13 y R es H a COR', donde R' es un alquilo saturado, no saturado o hidroxilado C8-22, y donde al menos un grupo R no es hidrógeno; teniendo un valor HLB no menor que 10; c) entre el 0,1 y el 60 % de uno o más compuestos que generan geles seleccionados de poliglicerol ésteres de ácidos grasos y/o ácidos no saturados de la fórmula: CH2OR-CHOR-CH2O-[CH2CHOR-CH2O-]NCH2-CHOR-CH2OR, donde n es un entero entre 0-10 y R=H a cor'', donde R'' es un alquilo saturado, no saturado o hidroxilado C8-22, y donde al menos un grupo R no es hidrógeno; teniendo un valor de HLB no mayor que 9; d) entre el 1 y el 60 % de uno o más compuestos co-formadores de gel seleccionados de macrogol glicerolésteres de triglicérido, glicérido parciales o ácido grasos o macrogol ésteres de ácidos grasos donde la cantidad promedio del óxido etileno reaccionado en la síntesis de estas sustancias está dentro de un rango entre 50 y 150 moles y concurrentemente, la relación entre los componentes b) y d) es entre 0,1: 1 a 10:1; e) 5,0 a 30 % de etanol, donde los porcentajes precedentes se seleccionan hasta un total del 100 %; y donde después de la dilución con agua, la formulación forma una dispersión de partículas de gel polimorfas que tienen una dimensión 0,2 a 500 micrones y una forma de dosis farmacéutica.
ARP030103268A 1999-08-17 2003-09-10 Formulaciones farmaceuticas para la administracion oral y topica y formas de dosis farmaceutica AR043106A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9919288A GB2355656B (en) 1999-08-17 1999-08-17 Pharmaceutical compositions for oral and topical administration

Publications (1)

Publication Number Publication Date
AR043106A2 true AR043106A2 (es) 2005-07-20

Family

ID=10859192

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP000104281A AR025324A1 (es) 1999-08-17 2000-08-18 Composiciones farmaceuticas para la administracion oral y topica
ARP030103268A AR043106A2 (es) 1999-08-17 2003-09-10 Formulaciones farmaceuticas para la administracion oral y topica y formas de dosis farmaceutica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP000104281A AR025324A1 (es) 1999-08-17 2000-08-18 Composiciones farmaceuticas para la administracion oral y topica

Country Status (40)

Country Link
US (1) US20070190132A1 (es)
EP (2) EP1334717B1 (es)
JP (2) JP2003507343A (es)
KR (2) KR100828748B1 (es)
CN (2) CN101406453A (es)
AR (2) AR025324A1 (es)
AT (2) ATE288766T1 (es)
AU (1) AU777740B2 (es)
BR (1) BR0013385A (es)
CA (2) CA2452118A1 (es)
CO (1) CO5380014A1 (es)
CY (1) CY1105318T1 (es)
CZ (2) CZ296591B6 (es)
DE (2) DE60018081T2 (es)
DK (2) DK1210119T3 (es)
EE (2) EE04955B1 (es)
EG (1) EG23994A (es)
ES (2) ES2237443T3 (es)
GB (1) GB2355656B (es)
HK (1) HK1049629A1 (es)
HR (1) HRP20020154B1 (es)
HU (1) HUP0203236A3 (es)
IL (4) IL158108A0 (es)
JO (1) JO2324B1 (es)
MX (1) MXPA02001631A (es)
NO (2) NO20020760L (es)
NZ (1) NZ517271A (es)
PE (1) PE20010636A1 (es)
PL (1) PL192769B1 (es)
PT (2) PT1210119E (es)
RU (2) RU2279894C2 (es)
SA (1) SA00210487B1 (es)
SG (1) SG143019A1 (es)
SI (1) SI1210119T1 (es)
SK (2) SK286083B6 (es)
TN (1) TNSN00173A1 (es)
UA (2) UA72539C2 (es)
UY (1) UY26303A1 (es)
WO (1) WO2001012229A1 (es)
ZA (2) ZA200308221B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2355656B (en) * 1999-08-17 2004-04-07 Galena As Pharmaceutical compositions for oral and topical administration
FR2826261B1 (fr) * 2001-06-26 2005-03-25 Lmd Composition a usage topique comprenant un produit cytotoxique et son utilisation dans le traitement de l'alopeche
DE10154464B4 (de) * 2001-11-08 2005-10-20 Max Delbrueck Centrum Oral verabreichbare pharmazeutische Zubereitung umfassend liposomal verkapseltes Taxol
KR20030065831A (ko) * 2002-02-01 2003-08-09 주식회사 태평양 사이클로스포린을 함유한 지속 방출형 약학적 조성물
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
EP1935407A1 (en) * 2002-12-03 2008-06-25 Elan Pharma International Limited Low viscosity liquid dosage forms
CN100337620C (zh) * 2002-12-04 2007-09-19 日清药业股份有限公司 含有辅酶q10的水溶性组合物
JP4518042B2 (ja) * 2002-12-04 2010-08-04 日油株式会社 コエンザイムｑ１０を含有する水溶性組成物の製造方法
AU2003299590B8 (en) * 2002-12-09 2010-04-08 Abraxis Bioscience, Llc Compositions and methods of delivery of pharmacological agents
US6979672B2 (en) * 2002-12-20 2005-12-27 Polichem, S.A. Cyclosporin-based pharmaceutical compositions
TW200616681A (en) * 2004-10-05 2006-06-01 Recordati Ireland Ltd Lercanidipine capsules
EP1806125B1 (en) * 2004-10-20 2011-08-03 Kao Corporation Liquid compositions for oral cavity
BRPI0608173A2 (pt) * 2005-02-24 2010-11-09 Elan Pharma Int Ltd composição, uso da mesma, e, método de produzir uma composição de docetaxel nanoparticulada ou análogo do mesmo
BRPI0921654A2 (pt) * 2008-11-28 2016-02-10 Advance Holdings Ltd formulação farmacêutica
DK2405892T3 (da) * 2009-03-12 2013-04-08 Advance Holdings Ltd Farmaceutisk formulering omfattende ketoprofen og en polyoxyalkylenester af en hydroxy-fedtsyre
KR101100933B1 (ko) * 2009-04-23 2012-01-02 한국기술교육대학교 산학협력단 솔더 볼 제거 장치
JP6763939B2 (ja) 2015-03-27 2020-09-30 アーチ・パーソナル・ケア・プロダクツ・エルピー パーソナルケア製品のための粘度増強組成物
CN112426403B (zh) * 2020-12-09 2021-09-17 南京天纵易康生物科技股份有限公司 一种口腔溃疡凝胶及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
US6007840A (en) * 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
CZ288631B6 (cs) * 1996-01-18 2001-08-15 Galena, A. S. Léčivé přípravky s obsahem cyklosporinu
CZ288739B6 (cs) * 1996-08-01 2001-08-15 Galena, A. S. Cyklosporin obsahující léčivé přípravky
CZ283516B6 (cs) * 1996-09-12 1998-04-15 Galena A.S. Léčivé přípravky, zejména pro vnitřní aplikaci, ve formě samomikroemulgujících terapeutických systémů
TR199902199T2 (xx) * 1997-03-12 2002-06-21 Abbott Laboratories Siklosporin tatbiki i�in hidrofilik ikili sistemler.
JP2001515491A (ja) * 1997-03-12 2001-09-18 アボツト・ラボラトリーズ 親油性化合物の投与のための親油性二成分系
PL191780B1 (pl) * 1997-07-29 2006-07-31 Upjohn Co Kompozycja farmaceutyczna w postaci samoemulgującej formulacji związków lipofilowych i samoemulgujące podłoże formulacji
US6063762A (en) * 1997-12-05 2000-05-16 Chong Kun Dang Corp. Cyclosporin-containing microemulsion preconcentrate composition
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
GB2355656B (en) * 1999-08-17 2004-04-07 Galena As Pharmaceutical compositions for oral and topical administration

Also Published As

Publication number Publication date
GB9919288D0 (en) 1999-10-20
DK1334717T3 (da) 2008-11-24
HRP20020154A2 (en) 2003-12-31
IL148200A (en) 2007-12-03
EE04954B1 (et) 2008-02-15
ES2311077T3 (es) 2009-02-01
ZA200201315B (en) 2004-06-30
MXPA02001631A (es) 2003-07-14
HUP0203236A2 (hu) 2003-01-28
IL148200A0 (en) 2002-09-12
EP1210119A1 (en) 2002-06-05
KR20050095651A (ko) 2005-09-29
WO2001012229A1 (en) 2001-02-22
CA2452118A1 (en) 2001-02-22
IL158108A (en) 2010-04-15
PT1210119E (pt) 2005-05-31
SK2482002A3 (en) 2002-12-03
ZA200308221B (en) 2004-09-29
CZ296591B6 (cs) 2006-04-12
EE200200075A (et) 2003-04-15
ES2237443T3 (es) 2005-08-01
RU2279895C2 (ru) 2006-07-20
PL353445A1 (en) 2003-11-17
AR025324A1 (es) 2002-11-20
TNSN00173A1 (en) 2005-11-10
GB2355656A (en) 2001-05-02
SI1210119T1 (en) 2005-06-30
CO5380014A1 (es) 2004-03-31
CN1382061A (zh) 2002-11-27
DE60322454D1 (de) 2008-09-11
EE200300371A (et) 2003-10-15
HUP0203236A3 (en) 2004-06-28
PE20010636A1 (es) 2001-06-02
NO20020760L (no) 2002-04-16
PT1334717E (pt) 2008-10-09
CN101406453A (zh) 2009-04-15
JP2004238399A (ja) 2004-08-26
JO2324B1 (en) 2005-09-12
NO20034778D0 (no) 2003-10-24
SK286083B6 (sk) 2008-03-05
US20070190132A1 (en) 2007-08-16
EG23994A (en) 2008-03-10
JP2003507343A (ja) 2003-02-25
EP1334717A2 (en) 2003-08-13
CZ296170B6 (cs) 2006-01-11
GB2355656B (en) 2004-04-07
DK1210119T3 (da) 2005-06-20
HRP20020154B1 (en) 2006-07-31
HK1049629A1 (zh) 2003-05-23
KR100828747B1 (ko) 2008-05-09
NO20034778L (no) 2002-04-16
EP1334717A3 (en) 2004-01-02
RU2003133451A (ru) 2005-04-20
SG143019A1 (en) 2008-06-27
AU777740B2 (en) 2004-10-28
NZ517271A (en) 2004-02-27
CZ2002575A3 (cs) 2003-05-14
BR0013385A (pt) 2002-05-07
ATE402691T1 (de) 2008-08-15
NO20020760D0 (no) 2002-02-15
UA75926C2 (en) 2006-06-15
PL192769B1 (pl) 2006-12-29
EP1334717B1 (en) 2008-07-30
AU6461300A (en) 2001-03-13
ATE288766T1 (de) 2005-02-15
IL158108A0 (en) 2004-03-28
CY1105318T1 (el) 2010-03-03
SA00210487B1 (ar) 2006-09-10
DE60018081D1 (de) 2005-03-17
EE04955B1 (et) 2008-02-15
UY26303A1 (es) 2001-03-16
KR100828748B1 (ko) 2008-05-09
CA2380951A1 (en) 2001-02-22
DE60018081T2 (de) 2006-01-05
RU2279894C2 (ru) 2006-07-20
EP1210119B1 (en) 2005-02-09
CA2380951C (en) 2010-03-23
KR20020059367A (ko) 2002-07-12
UA72539C2 (en) 2005-03-15

Similar Documents

Publication Publication Date Title
AR043106A2 (es) Formulaciones farmaceuticas para la administracion oral y topica y formas de dosis farmaceutica
US8716340B2 (en) Topical composition
US6500862B1 (en) Stable microemulsions for the administration of fatty acids to humans or to animals, and use of these microemulsions
NO20000467L (no) Farmasøytisk preparat i form av en selvemulgerende formulering for lipofile forbindelser
CO4930289A1 (es) Composiciones galenicas, en donde el ingrediente activo es un agente activo dificilmente soluble
KR890001521A (ko) 서방형 신규 제약 제제물
DK1173153T3 (da) Orale farmaceutiske præparater, som indeholder langkædede triglycerider og lipofile overfladeaktive midler
HUP0500843A2 (hu) Fokozott biológiai hasznosulású, szájon át hatásos taxánszármazékokat tartalmazó gyógyszerkészítmények
BR9810866A (pt) Composição farmacêutica em uma forma de formulação auto-emulsificante para compostos lipofìlicos
ES2177652T3 (es) Nuevas formas de preparacion de ciclosporina para la aplicacion oral con composicion simple y alta biodisponibilidad, y procedimiento para su obtencion.
KR101590072B1 (ko) 두타스테라이드를 포함하는 자가유화 약물전달 시스템용 조성물
PE20001499A1 (es) Composiciones farmaceuticas de n-benzoil-estaurosporina
AU2003248969A1 (en) Pharmaceutical formulation comprising cyclosporin, propylene glycol ester and non-ionic surfactant
KR970706803A (ko) 경구용 시클로스포린 제형(oral cyclosporin formulations)
UY28008A1 (es) Composiciones farmacéuticas para administración oral y tópica
MY130474A (en) Oral pharmaceutical compositions containing long-chain triglycerides and lipophilic surfactants

Legal Events

Date Code Title Description
FB Suspension of granting procedure